Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25207401
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Bremsstrahlung dose of 165Dy in radiosynovectomy
#MMPMID25207401
Manjunatha HC
J Appl Clin Med Phys
2014[Jul]; 15
(4
): 345?355
PMID25207401
show ga
There has been an increased interest in 165Dy radiossynovectomy, which emits
relatively high-energy (> 1 MeV) beta rays. The production of in vivo
bremsstrachlung radiation hazards warrants evaluation. The bremsstrahlung
component of the decay scheme of 165Dy has been traditionally ignored in internal
dosimetry calculations. We have estimated the bremsstrahlung dose of 165Dy
distributed in muscle and bone to body by various internal organs (adrenals,
brain, breasts, gallbladder wall, LLI wall, small intestine, stomach, ULI wall,
heart wall, kidneys, liver, lungs, muscle, ovaries, pancreas, red marrow, bone
surfaces, skin, spleen, testes, thymus, thyroid, urine bladder wall, uterus,
fetus, placenta, and total body) during radiosynovictomy. In the present study,
muscle and bone are considered to be source organs. These estimated values show
that the bremsstrahlung radiation absorbed dose contribution from an organ to
itself is very small compared to that originating from the beta source. However,
contribution to other organs is not always negligible, especially when large
amounts of 165Dy may be involved, such as in therapy applications. Hence the
component of the total dose due to bremsstrahlung dose should be considered in
radiosynovictomy or other therapy applications.
free
free
free
